ARUP Laboratories - Company Profile
Powered by 
All the data and insights you need on ARUP Laboratories in one report.
$295
- Save hours of research time and resources with
our up-to-date ARUP Laboratories Strategy Report
- Understand ARUP Laboratories position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ARUP Laboratories (ARUP) is a clinical and anatomical pathology reference laboratory. It is a nonprofit enterprise of the University of Utah and its Department of Pathology. The company provides several tests and test combinations in the fields of anatomic pathology, genetics, pain management, general oncology, hematologic oncology, hemostasis/thrombosis, immuno-hematology, molecular infectious disease, pediatric conditions, transplantation, and veterinary pathology. Its major clients include university teaching hospitals, children's hospitals, major commercial laboratories, regional hospital networks and clinics, group-purchasing organizations, military and government facilities. ARUP is headquartered in Salt Lake City, Utah, the US.
Headquarters
United States of America
Address
500 Chipeta Way, Salt Lake, Utah, 84108-1221
Website
www.aruplab.com
Telephone
1 801 5832787
No of Employees
4,000
Industry
Pharmaceuticals and Healthcare
ARUP Laboratories premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Anatomic Pathology Tests: | ARUP ATOP |
| Consultation Services | ARUP Consult |
| Cytopathology | ARUP Connect |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In June, the company announced that the U.S. Food and Drug Administration approved AAV5 DetectCDx as a companion diagnostic to aid in the selection of adult patients eligible to treat patients with ROCTAVIAN (valoctocogene roxaparvovec-rvox). |
| 2022 | Contracts/Agreements | In October, the company along with MacDonald, McConnell Dowel and Metro Trains Melbourne entered into partnership with the Level Crossing Removal Project to deliver a new Narre Warren Station and an elevated rail bridge to get rid of the Webb Street level crossing by 2025. |
| 2021 | Contracts/Agreements | In May, the company and TellBio Inc entered into a strategic agreement to use the development-stage biotechnology company’s TellDx circulating tumor cells (CTCs) technology in several research applications. |
Competitor Comparison
| Key Parameters | ARUP Laboratories | Laboratory Corp of America Holdings | Quest Diagnostics Inc | OpGen Inc | Athena Diagnostics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Salt Lake | Burlington | Secaucus | Rockville | Marlborough |
| State/Province | Utah | North Carolina | New Jersey | Maryland | Massachusetts |
| No. of Employees | 4,000 | 80,000 | 40,000 | 100 | - |
| Entity Type | Institution | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Jensen, M.D. | Chairman | Executive Board | - | - |
| Andy Theurer, BS, CPA | Chief Executive Officer | Senior Management | - | - |
| Kent C. Gordon | Chief Financial Officer | Senior Management | - | - |
| Jonathan Carr | Chief Compliance Officer | Senior Management | - | - |
| Jonathan R. Genzen, M.D., Ph.D. | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer